Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to darunavir/ritonavir for HIV low-level viremia
NL-OMON38997Phase 4Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Virological response at 24 weeks. Planned start Sep 2013; status: withdrawn.
02
Drugs
darunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON38997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38997.